헤더 로고

• All
• March 26 (Thu)
• March 27 (Fri)
• March 28 (Sat)

Day 1: March 26 (Thu)

• Advances and Insights in Molecular Monitoring for Myeloproliferative Neoplasms Hsin-An Hou
  National Taiwan University Hospital, Taiwan CV Abstract
• Evolving Treatment Paradigms in Early Myelofibrosis Winnie Teo
  Alexandra Hospital, Singapore CV Abstract
• Optimizing Treatment Strategies in Higher MF and Beyond Sung-Eun Lee
  College of Medicine, The Catholic University of Korea, Korea CV Abstract

Day 1: March 26 (Thu)

• Recent Advances in the Diagnosis and Management of Acquired Hemophilia A Shin Young Hyun
  Yonsei University College of Medicine, Korea CV Abstract
• Clinical Advances and Challenges in Gene Therapy for Hemophilia Ben Samelson-Jones
  The Children's Hospital of Philadelphia, USA CV Abstract
• Role of Bispecific Antibody in Hemophilia Claude Négrier
  University of Lyon, France CV Abstract

Day 1: March 26 (Thu)

• Integration of MRD and Genetics as a Therapeutic Guidepost in ALL Anthony Moorman
  Newcastle University, UK CV Abstract
• Modern Immunotherapeutics in B-ALL: BiTEs, ADCs, and Beyond Jae-Ho Yoon
  College of Medicine, The Catholic University of Korea, Korea CV
• Optimizing Frontline Therapy in Ph+ ALL: The Role of Ponatinib and Beyond Nicholas J. Short
  The University of Texas MD Anderson Cancer Center, USA CV Abstract

Day 1: March 26 (Thu)

• Mantle Cell Lymphoma Jaewon Hyung
  University of Ulsan College of Medicine, Korea CV Abstract
• Chronic Lymphocytic Leukemia Jongheon Jung
  National Cancer Center, Korea CV Abstract
• Marginal Zone Lymphoma Sang-A Kim
  Seoul National University College of Medicine, Korea CV Abstract

Day 1: March 26 (Thu)

• What Makes a Stem Cell and How Does It Go Bad John E. Dick
  University Health Network, Canada CV Abstract

Day 1: March 26 (Thu)

• Mechanism-Driven Combination Targeted Therapies for Diffuse Large B-cell Lymphoma Wyndham H. Wilson
  National Cancer Institute, USA CV Abstract

Day 1: March 26 (Thu)

• Recent Insights on DLBCL Treatment: Focused on Polatuzumab and Glofitamab Matthew Matasar
  Rutgers Cancer Institute, USA CV

Day 1: March 26 (Thu)

• Immunoglobulin Replacement in the Era of Cellular and Bispecific Therapies Ja Min Byun
  Seoul National University College of Medicine, Korea CV Abstract

Day 1: March 26 (Thu)

• Changing the Survival Landscape in RRMM with Novel ADC Sung-Hoon Jung
  Chonnam National University Medical School, Korea CV Abstract

Day 1: March 26 (Thu)

• Epcoritamab in 3L+ DLBCL: Updates on Clinical Trial and Real World Data in the Evolving DLBCL Treatment Pathway William Townsend
  University College London Hospitals NHS Foundation Trust, UK CV Abstract

Day 1: March 26 (Thu)

• Advancing CML Treatment with Clinical Insights on Asciminib Eri Matsuki
  Keio University School of Medicine, Japan CV Abstract

Day 1: March 26 (Thu)

• The Current State of Transplantation for Aplastic Anemia in Vietnam Han Viet Trung
  Bach Mai Hospital, Vietnam CV Abstract
• Recent Update of the Treatment of Aplastic Anemia in Thailand Ponlapat Rojnuckarin
  Chulalongkorn University, Thailand CV Abstract
• PNH Management in Korea: Therapeutic Options, Access and Real-World Outcomes Silvia Park
  College of Medicine, The Catholic University of Korea, Korea CV Abstract

Day 1: March 26 (Thu)

• Integrating Comprehensive Geriatric Assessment into Hematology Practice: Identifying Frailty and Optimizing Care for Older Adults Jung-Yeon Choi
  Seoul National University Bundang Hospital, Korea CV Abstract
• Redefining Risk in Elderly AML: A Geriatric Assessment-Based Approach Byung-Sik Cho
  College of Medicine, The Catholic University of Korea, Korea CV Abstract
• Psycho-Oncological Interventions in Geriatric Hematology: Enhancing Quality of Life Juhee Cho
  Samsung Comprehensive Cancer Center, Sungkyunkwan University, Korea CV Abstract

Day 1: March 26 (Thu)

• Engineered NK Cells for Optimal Anti-Tumor Immunotherapy Challice Bonifant
  Johns Hopkins University School of Medicine, USA CV Abstract
• Lessons from Hemophagocytic Lymphohistiocytosis: Taming the Cytokine Storm in CAR-T Cell Therapy Michael B. Jordan
  Cincinnati Children’s Hospital Medical Center, USA CV
• Tumor-Marrow Axis: Myeloid Reprogramming from Suppression to Activation Seunghee Kim-Schulze
  Icahn School of Medicine at Mount Sinai, USA CV Abstract

Day 1: March 26 (Thu)

• FLT3-Positive AML Ik-Chan Song
  Chungnam National University College of Medicine, Korea CV Abstract
• B-cell ALL with HIgh Risk Features in Adults Dong Won Baek
  Kyungpook National University School of Medicine, Korea CV Abstract
• Understanding and Clinical Approach to Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Hee Young Ju
  Sungkyunkwan University School of Medicine, Korea CV Abstract

Day 1: March 26 (Thu)

• Insights into DDX41 Mutations: Relatively Common Genetic Aberrations in Korean MDS Patients Hongtae Kim
  Ulsan National Institute of Science and Technology (UNIST), Korea CV Abstract
• Few Drug Approvals in MDS: Lessons and Insights from a Decade of Clinical Trials Maximilian Stahl
  Yale University School of Medicine, USA CV Abstract
• Clinical Approach to Relapsed or Refractory Lower-Risk Myelodysplastic Syndromes Valeria Santini
  University of Florence, Italy CV Abstract

Day 1: March 26 (Thu)

• Recent Advances in the Genetics of Telomere Biology Disorders Sharon A. Savage
  National Institutes of Health, USA CV Abstract
• Clonal Hematopoiesis in the Short Telomere Syndromes Kristen E. Schratz
  Johns Hopkins University School of Medicine, USA CV Abstract
• Current Status of Telomere Biology Disorders in Inherited Bone Marrow Failure Inderjeet Dokal
  Queen Mary University of London, UK CV Abstract

Day 1: March 26 (Thu)

• Next-Generation Effector Cells in Myeloma Immunotherapy Hyunsoo Cho
  Seoul National University College of Medicine, Korea CV Abstract
• Natural Killer Cell-Based Immunotherapy in Multiple Myeloma Seung-Hwan Lee
  University of Ottawa, Canada CV Abstract
• Preclinical Optimization of T Cell Redirected Therapy Marta Chesi
  Mayo Clinic, USA CV Abstract

Day 1: March 26 (Thu)

• Procedures and Interpretation of Bone Marrow Examination Seung Yeob Lee
  Jeonbuk National University Medical School, Korea CV Abstract
• Diagnostic and Monitoring Approaches Focused on Minimal Residual Disease Miyoung Kim
  University of Ulsan College of Medicine, Korea CV Abstract
• Laboratory Tests Performed in Blood Bank before and after Hematopoietic Stem Cell Transplantation Dong Wook Jekarl
  College of Medicine, The Catholic University of Korea, Korea CV Abstract